Acyclovir has been shown to be superior to IDU in the treatment of experimental corneal infections with HSV in the rabbit'5 and has also shown promise in treating dendritic ulceration in man. In patients treated with minimal wipe debridement Jones et al. '6 showed that topical treatment with acyclovir prevented early recurrences in comparison with placebo.
Idoxuridine (IDU) has been used for the treatment of herpes simplex keratitis since 1962,1 and its efficacy in treating this infection has been established.
Results from controlled trials indicate an average cure rate of 76%.2-10 However, the drug is known to produce toxic effects, including follicular conjunctivitis, contact dermatitis, epithelial keratitis, and occlusion of the punctum." More effective and less toxic alternatives have been sought. Adenine arabinoside (ara-A) has a similar level of efficacy to IDU,6 while trifluorothymidine (F3TDR) is somewhat more effective. 12 Acyclovir (Zovirax, 9-(2-hydroxyethoxymethyl)-guanine) was developed by Elion, Schaeffer, and Bauer." 14 In vitro acyclovir is over 10 times more active against herpes simplex virus (HSV) type I than either IDU or F3TDR. The first step in the phosphorylation of acyclovir to the active triphosphate is carried out by viral specified thymidine kinase. Acyclovir triphosphate inhibits HSV DNA polymerase 10-30 times more effectively than cellular DNA polymerase, resulting in preferential inhibition of viral DNA synthesis.
Acyclovir has been shown to be superior to IDU in the treatment of experimental corneal infections with HSV in the rabbit'5 and has also shown promise in treating dendritic ulceration in man. In patients treated with minimal wipe debridement Jones et al. '6 showed that topical treatment with acyclovir prevented early recurrences in comparison with placebo. All ulcers treated with acyclovir healed, while ulcers in 7 (24l1°) of 29 patients were not improved or had become worse after 4 days' treatment with IDU (P<001, Cox's logit procedure). These patients were withdrawn from the study. The number of days taken to heal in patients treated with acyclovir ranged from 2 to 9 days (average 4 4 days), compared with 3 to 17 days (average 9 2 days) for patients treated with IDU (Tables 2 and 3 ). The cumulative rate of healing for both treatments is given in Fig. 1 . The difference between the 2 groups in terms of healing rate was significant (P<0-01, log rank analysis). Two of 30 patients treated with acyclovir and 20 of 29 patients treated with IDU took more than 6 days to heal.
Five patients presented with uveitis in the group treated with acyclovir, which resolved in 3-11 days (average 7 days). Uveitis was present in 3 patients treated with IDU and developed during treatment in a further 2. Two patients were withdrawn from the study, while the other 3 resolved, respectively in 2, 7, and 23 days.
Symptoms of pain, photophobia, lachrymation, and grittiness resolved within 11 days in all except 4 patients-all of whom were treated with IDU. For each symptom, resolution was more rapid after treatment with acyclovir (Table 4) . Stinging on initial application of the ointment was noted by 8 patients treated with acyclovir and by 2 patients treated with IDU. One patient treated with acyclovir complained of a sore tongue. Watering of the eye was experienced by a further 2 patients treated with IDU. This necessitated dilatation of the puncta and syringing of the duct in 1 patient. Superficial punctate epitheliopathy was noted in 6 other patients treated with IDU. Summaries of side effects for both treatment groups are given in Tables 2 and 3 .
Patients in both groups have been followed up for 2-5-13 months (average 8-7 months acyclovir, 8-9 months IDU). One recurrence occurred 3 weeks after treatment with acyclovir, and 2 patients had recurrences after treatment with IDU, at 8 weeks and 4 months respectively. 
